Why the study?
Does alirocumab reduce platelet reactivity in patients with acute MI undergoing PCI treated with potent P2Y12 inhibitors and high-intensity statins?
Does alirocumab reduce platelet reactivity in patients with acute MI undergoing PCI treated with potent P2Y12 inhibitors and high-intensity statins?
In patients with acute MI undergoing PCI and treated with potent P2Y12 inhibitors, the addition of alirocumab significantly reduced LDL-C but did not significantly reduce platelet reactivity.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ortega‐Paz et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: